Skip to main content

Table 3 Adverse events during the follow-up period

From: Treatment of diabetic nephropathy with Tripterygium wilfordii Hook F extract: a prospective, randomized, controlled clinical trial

 

TwHF group (n = 34)

Valsartan group (n = 31)

Any adverse event (n,%)

13 (38.3)

12 (38.7)

Vomiting (n,%)

1 (2.94)

0 (0.00)

Liver dysfunction (n,%)

3 (8.82)

0 (0.00)

Decrease in WBC count (n,%)

1 (2.94)

0 (0.00)

Photosensitive dermatitis (n,%)

0 (0.00)

1 (3.22)

Hyperkalemia (n,%)

8 (23.53)

10 (32.2)

K+ > 6.0 (n,%)

3 (8.82)

2 (6.45)

Doubling of serum creatinine (n,%)

0 (0.00)

1 (3.22)